High-sensitivity drug impurity analysis and detection method and system

Through the impurity detection network that works in collaboration with multiple detection channels, combined with the analysis of chromatography, spectroscopy and mass spectrogram, the problem of low detection accuracy of traditional Chinese medicines in the existing technology is solved, and more comprehensive and accurate drug impurity detection is achieved, ensuring drug quality .

CN118967668AInactive Publication Date: 2024-11-15KEYPOINT PHARM TECH (QIDONG) CO LTD

Patent Information

Application Number
CN202411428244.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-14
Publication Date
2024-11-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The accuracy of existing drug testing methods is low and the testing is not comprehensive enough, resulting in low drug quality.

Method used

Using multiple detection channels (chromatography, spectroscopy, mass spectroscopy) to work in concert, sample data is generated through random sampling, sample chromatogram, spectrogram, and mass spectrogram are generated simultaneously, and impurity signal evaluation is combined with the sensitivity of the three. Adjust and extract drug impurities test results.

Benefits of technology

It improves the comprehensiveness and accuracy of drug testing, ensures the quality of drugs, and reduces missed detection and misjudgment of impurities.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118967668A_ABST
    Figure CN118967668A_ABST
Patent Text Reader

Abstract

The invention discloses a high-sensitivity drug impurity analysis and detection method and system, and relates to the technical field of drug detection.The method comprises the steps that sampling is conducted based on drug batch information, and sample data is generated; constructing an impurity detection network, and generating an impurity signal; synchronizing the plurality of sample data to a chromatographic detection channel for analysis to generate a sample chromatogram; synchronizing a plurality of sample data to the spectrum detection channel for analysis, and generating a sample spectrogram; synchronizing the plurality of sample data to the mass spectrum detection channel for analysis, and generating a sample mass spectrum; evaluating the impurity signal, generating a sample impurity evaluation result, and extracting a drug impurity detection result. The technical problem of low medicine quality caused by low accuracy and incomplete detection of a detection method in the prior art is solved, and the technical effects of improving the comprehensiveness and accuracy of medicine detection and guaranteeing the medicine quality are achieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of drug detection, and in particular to a high-sensitivity drug impurity analysis detection method and system. Background Art

[0002] In the critical field of drug production, accurate detection of impurities is the core link to ensure drug quality and patient safety, and its importance is self-evident. Traditional drug impurity detection methods often present a single characteristic, usually relying solely on a specific technology such as chromatography, spectroscopy or mass spectrometry. However, each single detection technology has its limitations, resulting in incomplete and inaccurate test results.

[0003] The existing technology has the technical problems of low accuracy of detection methods and insufficient comprehensiveness of detection, which leads to poor quality of drugs. Summary of the invention

[0004] The present application provides a highly sensitive drug impurity analysis and detection method and system, which is used to solve the technical problems in the prior art that the detection methods have low accuracy and incomplete detection, thereby leading to poor drug quality.

[0005] In view of the above problems, the present application provides a highly sensitive drug impurity analysis and detection method and system.

[0006] In a first aspect of the present application, a highly sensitive drug impurity analysis and detection method is provided, the method comprising: Based on multiple drug batch information, random sampling is performed to generate multiple sample data; an impurity detection network is constructed, wherein the impurity detection network is used to perform impurity detection on the multiple sample data to generate impurity signals, and the impurity detection network includes a chromatographic detection channel, a spectral detection channel, and a mass spectrometry detection channel; the multiple sample data are synchronized to the chromatographic detection channel for analysis to generate a sample chromatogram, wherein the sample chromatogram has a first sensitivity; the multiple sample data are synchronized to the spectral detection channel for analysis to generate a sample spectrum, wherein the sample spectrum has a second sensitivity; the multiple sample data are synchronized to the mass spectrometry detection channel for analysis to generate a sample mass spectrum, wherein the sample mass spectrum has a third sensitivity; based on the first sensitivity, the second sensitivity, and the third sensitivity, the impurity signal is evaluated in combination with the sample chromatogram, the sample spectrum, and the sample mass spectrum to generate a sample impurity evaluation result; the first sensitivity, the second sensitivity, and the third sensitivity are adjusted according to the sample impurity evaluation result, and the drug impurity detection result is extracted according to the sensitivity adjustment result.

[0007] The second aspect of the present application provides a highly sensitive drug impurity analysis and detection system, the system comprising: A sample data generation module, wherein the sample data generation module randomly samples based on multiple drug batch information to generate multiple sample data; an impurity detection network construction module, wherein the impurity detection network construction module is used to construct an impurity detection network, wherein the impurity detection network is used to perform impurity detection on the multiple sample data to generate impurity signals, wherein the impurity detection network comprises a chromatographic detection channel, a spectral detection channel, and a mass spectrometry detection channel; a sample chromatogram generation module, wherein the sample chromatogram generation module is used to synchronize the multiple sample data to the chromatographic detection channel for analysis to generate a sample chromatogram, wherein the sample chromatogram has a first sensitivity; a sample spectral graph generation module, wherein the sample spectral graph generation module is used to synchronize the multiple sample data to the spectral detection channel for analysis to generate a sample spectral graph, wherein the sample a sample mass spectrum generating module, the sample mass spectrum generating module being used to synchronize the multiple sample data to the mass spectrometry detection channel for analysis to generate a sample mass spectrum, the sample mass spectrum having a third sensitivity; a sample impurity evaluation result generating module, the sample impurity evaluation result generating module evaluating the impurity signal based on the first sensitivity, the second sensitivity, the third sensitivity in combination with the sample chromatogram, the sample spectrum and the sample mass spectrum to generate a sample impurity evaluation result; a drug impurity detection result extraction module, the drug impurity detection result extraction module being used to adjust the first sensitivity, the second sensitivity and the third sensitivity according to the sample impurity evaluation result, and extract the drug impurity detection result according to the sensitivity adjustment result.

[0008] One or more technical solutions provided in this application have at least the following technical effects or advantages: Based on multiple drug batch information, random sampling is performed to generate multiple sample data; an impurity detection network is constructed to perform impurity detection on multiple sample data to generate impurity signals; multiple sample data are synchronized to the chromatographic detection channel for analysis to generate sample chromatograms; multiple sample data are synchronized to the spectrum detection channel for analysis to generate sample spectrum graphs; multiple sample data are synchronized to the mass spectrum detection channel for analysis to generate sample mass spectrograms; the impurity signals are evaluated to generate sample impurity evaluation results; the first sensitivity, the second sensitivity, and the third sensitivity are adjusted according to the sample impurity evaluation results, and drug impurity detection results are extracted according to the sensitivity adjustment results. The technical effect of improving the comprehensiveness and accuracy of drug detection and ensuring drug quality is achieved. BRIEF DESCRIPTION OF THE DRAWINGS

[0009] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the following briefly introduces the drawings required for use in the description of the embodiments. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.

[0010] Figure 1 A schematic diagram of a process flow of a highly sensitive drug impurity analysis and detection method provided in an embodiment of the present application; Figure 2 A schematic diagram of the structure of a high-sensitivity pharmaceutical impurity analysis and detection system provided in an embodiment of the present application.

[0011] Explanation of the accompanying drawings: sample data generating module 10, impurity detection network building module 20, sample chromatogram generating module 30, sample spectrum generating module 40, sample mass spectrum generating module 50, sample impurity assessment result generating module 60, drug impurity detection result extraction module 70. DETAILED DESCRIPTION

[0012] The present application provides a highly sensitive drug impurity analysis and detection method and system to solve the technical problems in the prior art of low accuracy and incomplete detection, which lead to poor drug quality.

[0013] The technical solutions in the embodiments of the present application will be described clearly and completely below in conjunction with the drawings in the embodiments of the present application. Obviously, the described embodiments are only part of the embodiments of the present application, not all of the embodiments. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of this application.

[0014] Embodiment 1 like Figure 1 As shown, the present application provides a highly sensitive drug impurity analysis and detection method, the method comprising: Step S100: Perform random sampling based on multiple drug batch information to generate multiple sample data.

[0015] Specifically, first obtain relevant information of multiple drug batches, including the production time, batch number, manufacturer, drug specifications, etc. of the drug. A certain number of samples are selected from these drug batches using random sampling. Random sampling can ensure that the selected samples are representative and avoid human bias. During the sampling process, certain sampling rules and standards need to be followed, such as sampling from each batch according to a certain proportion, or determining the sample to be drawn according to a specific random number generation algorithm. After the extraction is completed, detailed data collection is performed on each selected sample. These data include the physical properties of the drug (such as appearance, color, shape, size, etc.), chemical properties (such as ingredient content, pH value, etc.), microbial indicators, and other aspects, thereby generating multiple sample data to provide basic materials for subsequent impurity detection and analysis.

[0016] Step S200: constructing an impurity detection network, wherein the impurity detection network is used to perform impurity detection on the plurality of sample data to generate an impurity signal, and the impurity detection network comprises a chromatographic detection channel, a spectral detection channel, and a mass spectrometry detection channel.

[0017] Specifically, a complex network architecture dedicated to drug impurity detection is constructed, and the chromatographic detection channel is an important component. It uses the difference in the distribution coefficient of different substances between the stationary phase and the mobile phase to achieve separation. For example, in the common high-performance liquid chromatography (HPLC) or gas chromatography (GC), during the detection process, the various components in the sample will be pushed by the mobile phase, and according to the different degrees of interaction with the stationary phase, they will be eluted at different times to form characteristic chromatographic peaks. Each peak represents a component, and its peak area, peak height and retention time are very important for judging the existence and content of impurities. The spectral detection channel obtains information by means of the interaction between matter and light. For example, the ultraviolet-visible spectrum (UV-Vis) reflects the electronic transition in the molecule by measuring the absorption degree of the substance to ultraviolet and visible light of different wavelengths, thereby revealing the structure and functional group information of the compound. The infrared spectrum (IR) can detect the vibration and rotation energy level changes of the molecule, which is of great significance for determining the type of chemical bond and the skeleton structure of the molecule. In some cases, the fluorescence spectrum can detect impurities with fluorescent properties. The mass spectrometry detection channel is a powerful analytical tool. It first converts sample molecules into ions, and then separates and detects them according to the mass-to-charge ratio (m / z) of the ions. By measuring the abundance and mass-to-charge ratio of the ions, the molecular weight and structure of the molecules can be accurately determined. Tandem mass spectrometry (MS / MS) technology can further fragment and analyze specific ions to provide more detailed structural information, which is very helpful for the identification of complex impurities. These three detection channels do not operate in isolation, but work together in the impurity detection network. When multiple sample data are input into this network, the chromatographic detection channel quickly separates the different components in the sample and generates a preliminary component separation map; the spectral detection channel simultaneously captures the spectral characteristics of each component and provides information about the molecular structure and functional groups; the mass spectrometry detection channel performs accurate molecular weight and structural analysis on key components. Finally, by integrating the detection results of these three channels, an impurity signal that can accurately indicate the presence, type and content of impurities is generated. The three work together to greatly improve the detection sensitivity of trace impurities in drugs and effectively reduce the missed detection and misjudgment of impurities.

[0018] Step S300: synchronizing the plurality of sample data to the chromatographic detection channel for analysis to generate a sample chromatogram having a first sensitivity.

[0019] Specifically, the previously acquired multiple sample data are simultaneously transmitted to the chromatographic detection channel in the impurity detection network. The chromatographic detection channel processes and analyzes these sample data. It uses the distribution differences between the stationary phase and the mobile phase of different components in the sample to make each component move at different speeds in the chromatographic column, thereby achieving separation. After separation and detection, a corresponding sample chromatogram will be generated, which reflects the distribution of different components in the sample. The "first sensitivity" mentioned here means that the chromatographic detection channel can detect relatively low concentrations of components when analyzing the sample, and has a certain detection sensitivity. For example, if the content of a certain impurity in the sample is extremely low, but because the first sensitivity of the chromatographic detection channel is high, the corresponding peak can still be displayed in the chromatogram and thus detected. This is crucial for discovering trace impurities and ensuring the quality of drugs.

[0020] Step S400: synchronizing the plurality of sample data to the spectral detection channel for analysis to generate a sample spectrum graph, wherein the sample spectrum graph has a second sensitivity.

[0021] Specifically, the acquired data of multiple samples are synchronously transmitted to the spectral detection channel in the impurity detection network. The spectral detection channel analyzes by measuring the absorption, emission or scattering of light of a specific wavelength by the sample. Different substances have unique spectral characteristics. The spectral detection channel uses this characteristic to identify and distinguish the various components in the sample. After the analysis is completed, the corresponding sample spectrum is generated, which shows the optical response of the sample at different wavelengths. The "second sensitivity" mentioned means that this spectral detection channel can detect relatively small changes in optical signals when detecting samples, reflecting its sensitivity to the detection of specific components. For example, some impurities with very small contents will cause slight spectral changes in the sample at a specific wavelength. Since the spectral detection channel has a high second sensitivity, it can capture this subtle change, thereby helping to detect these trace impurities. This is of great significance for ensuring the purity and quality control of drugs.

[0022] Step S500: synchronizing the plurality of sample data to the mass spectrometry detection channel for analysis to generate a sample mass spectrum having a third sensitivity.

[0023] Specifically, the acquired data of multiple samples are also simultaneously input into the mass spectrometry detection channel in the impurity detection network. The working principle of the mass spectrometry detection channel is to first convert the molecules in the sample into ions, and then separate and detect them according to the mass-to-charge ratio of the ions. After a series of processing and analysis, the corresponding sample mass spectrum will be generated. The mass spectrum presents information such as the mass-to-charge ratio and relative abundance of different ions in the sample. The "third sensitivity" mentioned here means that the mass spectrometry detection channel can detect very low concentrations of ions in the sample and has a high perception of tiny mass changes. For example, for some extremely trace impurities, the ions they produce are only a very small peak in the sample mass spectrum, but due to the third sensitivity of the mass spectrometry detection channel, they can still be effectively detected and identified, providing a key basis for accurately analyzing the impurity components in drugs.

[0024] Step S600: Evaluate the impurity signal based on the first sensitivity, the second sensitivity, the third sensitivity in combination with the sample chromatogram, the sample spectrum, and the sample mass spectrum to generate a sample impurity evaluation result.

[0025] Specifically, the first sensitivity (from the chromatographic detection channel), the second sensitivity (from the spectral detection channel) and the third sensitivity (from the mass spectrometry detection channel) obtained in the previous steps are comprehensively considered. These sensitivity values ​​reflect the ability and sensitivity of each detection channel to detect impurities. At the same time, the generated sample chromatogram, sample spectrum and sample mass spectrum are combined. From the sample chromatogram, information such as the separation and relative content of different components can be obtained; the sample spectrum can provide the characteristics of molecular structure and functional groups; the sample mass spectrum gives key data such as the mass-to-charge ratio and relative abundance of ions. Based on this rich information, a comprehensive and in-depth evaluation of the detected impurity signal is carried out, including the intensity of the impurity signal (reflecting the amount of impurities) and clarity (indicating the clarity and recognizability of the impurity signal). Through such a comprehensive evaluation, an accurate and reliable sample impurity evaluation result is finally generated, providing an important basis for the quality judgment and subsequent processing of drugs.

[0026] Step S700: adjusting the first sensitivity, the second sensitivity, and the third sensitivity according to the sample impurity evaluation result, and extracting the drug impurity detection result according to the sensitivity adjustment result.

[0027] Specifically, this step optimizes the sensitivity setting of the detection based on the sample impurity evaluation results obtained previously. First, according to the sample impurity evaluation results, analyze whether the current first sensitivity, second sensitivity and third sensitivity are accurate and effective enough to detect impurities. If the evaluation results show that some impurities have not been fully detected, or there are large errors in the test results, it is necessary to adjust these three sensitivities. The purpose of the adjustment is to make the detection more accurate and sensitive to better adapt to the characteristics and content of impurities in different samples. After completing the sensitivity adjustment, the drug impurity detection results are extracted from the adjusted results. Here, the test results with the highest sensitivity are selected as the final drug impurity detection results. This is because the test results with the highest sensitivity can usually more accurately reflect the true situation of impurities, especially for trace or difficult to detect impurities. For example, if after adjustment, the sensitivity of the mass spectrometry detection channel performs best when detecting a specific impurity, then the result of the mass spectrometry detection channel is selected as the final detection conclusion about the impurity. Through such adjustments and selections, it is possible to ensure that the most reliable and accurate drug impurity detection results are obtained, providing strong support for drug quality control.

[0028] In a possible implementation, step S100 further includes: Step S110: Retrieve the production process of the target drug to determine multiple drug batch information.

[0029] Step S120: traverse the plurality of drug batch information and extract according to the detection requirements of the target drug to determine N drug batch information, where N is an integer greater than 0.

[0030] Step S130: Random sampling is performed according to the N drug batch information to obtain M sampling results. The M sampling results correspond to the N drug batch information, and M is an integer greater than or equal to N.

[0031] Step S140: Perform sample identification based on the M sampling results to generate multiple sample data.

[0032] Specifically, the complete production process information of the target drug is obtained from the database, archive records or other storage systems of drug production. The production process includes the procurement of raw materials, the time sequence of production, the operation details of each production link (such as temperature, pressure, reaction time and other process parameters), the inspection results of intermediate products, the output time of finished products, and the basis for batch division. By sorting out and analyzing these detailed information, it is possible to identify the different batches of drugs formed in the production process. Each batch has its specific production time range, adopted process conditions and possible differences.

[0033] A comprehensive and detailed review and analysis of the previously acquired drug batch information is conducted. First, the total number of batches must be considered. If there are a large number of batches, it is impossible to test all batches, and they need to be screened according to certain rules. Testing resources are also an important consideration, including the available number of testing equipment, the number of testing personnel, and the time and cost required for testing. If testing resources are limited, representative or key batches need to be selected for testing. The purpose of the test will also affect the extraction of batches. For example, if the purpose is to verify the impact of a new production process on drug quality, batches produced using a new process will be selected; if the purpose is to investigate the stability of product quality within a certain period of time, batches within that period of time will be selected. Taking these factors into consideration, N batches that meet the requirements are screened out from a large number of drug batch information. N is an integer greater than 0, indicating the final number of batches that need to be tested.

[0034] Random sampling is performed based on the information of N determined drug batches. During the sampling process, the key information of each sample is recorded in detail. The sampling time records the specific moment when the sample is obtained, which is important for tracking and analyzing possible time-related factors. The sampling location indicates from which specific part of the drug batch the sample is obtained, such as the upper, middle or lower part of the drug packaging. The sampling volume specifies the number of samples obtained. Through such random sampling, M sampling results are finally obtained. Among these M sampling results, it is ensured that at least one sample is taken from each drug batch. Since each batch has at least one sample and there will be more, M is an integer greater than or equal to N. There is a clear correspondence between the M sampling results and the N drug batch information, which enables the sampling results to be accurately traced back to specific batches in the future, so as to carry out targeted analysis and evaluation.

[0035] Sample identification is carried out for the M sampling results obtained above. There are various ways to identify, such as assigning a unique number to each sample, attaching a label containing batch information and sample serial number, entering a specific identification code in an electronic database, etc. Through these identification operations, each sampling result is converted into a sample with clear identity information. At the same time, during the identification process, other information related to the sample, such as sampling time, sampling location, sampling volume, etc., will be associated and recorded with the identification. Ultimately, these M sampling results that have been identified form multiple complete sample data, providing a clear and accurate basis for subsequent testing, analysis, storage, and traceability.

[0036] In a possible implementation, step S600 further includes: Step S610: Analyze the sample chromatogram based on the first sensitivity to obtain a first impurity signal intensity.

[0037] Step S620: Analyze the sample spectrum based on the second sensitivity to obtain a second impurity signal intensity.

[0038] Step S630: Analyze the sample mass spectrum based on the third sensitivity to obtain a third impurity signal intensity.

[0039] Step S640: defining a detection evaluation index according to the first impurity signal strength, the second impurity signal strength, and the third impurity signal strength.

[0040] Step S650: performing signal consistency verification on the impurity signal according to the detection evaluation index to generate a detection verification result.

[0041] Step S660: Add the detection verification result to the sample impurity assessment result.

[0042] Specifically, the first sensitivity characteristics of the chromatographic detection channel are combined with the impurity-related information contained in the sample chromatogram for analysis. Focus on key information such as the retention time, peak height, and peak area of ​​the impurity peak. The retention time is used to determine the type of impurity, and different impurities have specific retention times under specific chromatographic conditions. The peak height represents the maximum response value of the impurity signal at the retention time, which is usually related to the concentration of the impurity. The peak area comprehensively reflects the total amount of impurities in the entire detection process. Combined with the first sensitivity, that is, consider the detection ability and sensitivity of the chromatographic detection channel to impurities of different concentrations. Measure the area of ​​the impurity chromatographic peak, and calculate the impurity content based on the corresponding relationship between the area size and the known standard, so as to obtain the first impurity signal intensity.

[0043] The analysis is carried out based on the second sensitivity of the spectral detection channel and the obtained sample spectrum. Focus on the absorption or emission characteristics of impurities at specific wavelengths. Different impurity molecules have unique electronic structures, so they will show specific absorption or emission patterns under the irradiation of light of specific wavelengths. The intensity, shape, position and other characteristics of the absorption peaks or emission peaks at these specific wavelengths in the sample spectrum are studied in detail. Combined with the second sensitivity, that is, the detection and resolution ability of the spectral detection channel for absorption or emission signals of different intensities. Based on the calculation method of spectroscopy principles, the absorption or emission characteristics of impurities in the spectrum are converted into a numerical value that can quantitatively characterize the impurity content or concentration. This value is the second impurity signal intensity.

[0044] The mass spectrum shows the mass-to-charge ratio and relative abundance of different ions in the sample. According to the expected molecular weight or characteristic fragment ions of the target impurity, the corresponding ion peak is found in the mass spectrum. Then, combined with the third sensitivity, the detection sensitivity and resolution of the mass spectrometry detection channel to these specific ions are considered. The relative content of the impurity ions is quantitatively evaluated by measuring the height and area of ​​the ion peak or using more complex mass spectrometry data analysis methods, such as isotope distribution analysis and multiple reaction monitoring (MRM) data processing, and the quantitative information related to the impurity ions is converted into a value that can reflect the amount of impurities present. This value is the third impurity signal intensity.

[0045] The detection evaluation index is defined by comprehensively considering the first impurity signal intensity, the second impurity signal intensity and the third impurity signal intensity obtained previously. The mean, median, standard deviation and other statistics of the three impurity signal intensities are calculated to understand the overall central tendency and dispersion. Then, the three intensity values ​​are compared and combined. For example, the ratio between them is calculated to evaluate the relative contribution of different detection methods to impurity detection, and the threshold range is set. If any impurity signal intensity exceeds or falls below a specific threshold, it is considered abnormal.

[0046] Compare the key features of impurity signals in different detection channels (chromatography, spectrum, mass spectrometry). For the chromatographic detection channel, the retention time of the impurity signal will be checked. The retention time is the time when a specific impurity is eluted in the chromatographic column. If the retention time of the same impurity is the same or consistent within an acceptable error range in different levels of detection or different detection channels, it means that the signal is consistent. For the spectral detection channel, the characteristic wavelength will be focused on. Different impurities have specific absorption or emission spectra at specific wavelengths. If the characteristic wavelengths corresponding to the same impurity in different detections are the same, it means that the signal is consistent. For the mass spectrometry detection channel, the characteristic fragment ions are focused on. Each impurity will produce specific fragment ions in the mass spectrum. If these characteristic fragment ions are the same in multiple detections, the consistency of the signal can also be proved. If it is found through comparison that the same impurity signal is detected in multiple detection channels, that is, the retention time, characteristic wavelength and characteristic fragment ions are consistent with each other, then the credibility of the existence of the impurity is greatly increased. Finally, based on these consistency verification results, the detection verification results are generated. This result may indicate that the impurity signal is highly consistent, thereby confirming the existence of the impurity with high reliability; or if inconsistencies are found, further analysis and troubleshooting are required.

[0047] The generated test verification results are merged into the sample impurity evaluation results. The purpose of this is to make the sample impurity evaluation results more comprehensive and complete. The test verification results can provide important information about the consistency and reliability of the impurity signal for the overall evaluation. After adding, the sample impurity evaluation results not only include the analysis of the impurity signal intensity, type, etc., but also incorporate the verification of the consistency between different detection channels. This helps to more accurately judge the true status of impurities in the sample and provide a more sufficient and powerful basis for subsequent decisions, such as drug quality determination, production process improvement, and formulation of quality control measures.

[0048] In a possible implementation, step S610 further includes: Step S611: setting a signal-to-noise ratio standard based on the first sensitivity.

[0049] Step S612: Identify and extract impurity peaks from the sample chromatogram based on a baseline correction algorithm, where the impurity peaks include impurity retention time and impurity peak height.

[0050] Step S613: Calculate the impurity peak area according to the impurity retention time and the impurity peak height.

[0051] Step S614: Determine whether the impurity peak area meets the signal-to-noise ratio standard.

[0052] Step S615: If the impurity peak area meets the signal-to-noise ratio standard, output the first impurity signal strength according to the impurity peak area.

[0053] Specifically, a signal-to-noise ratio standard is set for the first sensitivity. The signal-to-noise ratio refers to the ratio of the signal (here, the signal of the impurity peak) to the noise (background interference, etc.). Setting a reasonable signal-to-noise ratio standard helps to distinguish effective impurity signals from noise and improve the accuracy of detection.

[0054] The baseline correction algorithm is used to process the sample chromatogram to identify and extract the impurity peak. The main function of the baseline correction algorithm is to eliminate or reduce background interference such as baseline drift and fluctuation in the chromatogram, so that the impurity peak can be identified and measured more clearly and accurately. After being processed by the baseline correction algorithm, the relevant information of the impurity peak can be extracted from the complex chromatogram. Among them, the impurity retention time refers to the time it takes for the impurity to be eluted in the chromatographic column. It is an important parameter for qualitative analysis of the impurity type. Different impurities have specific retention times. By comparing with the retention time of known standard substances, the type of impurity can be preliminarily determined. The impurity peak height indicates the maximum value of the signal response at the time when the impurity is eluted. The peak height reflects the concentration or content of the impurity to a certain extent.

[0055] The impurity peak area is calculated using the previously acquired impurity retention time and impurity peak height. The impurity peak area is usually calculated using the mathematical integration method, which regards the chromatographic peak as a combination of a series of tiny rectangles or trapezoids. According to the shape of the impurity peak and the distribution of data points, the integration interval is determined, that is, from the starting point of the impurity peak (the starting point of the retention time) to the end point (the end point of the retention time). Then, for each data point, the area of ​​each tiny rectangle or trapezoid is calculated based on the time interval between it and the adjacent data point and the corresponding signal intensity (peak height). Finally, all these tiny areas are added up to get the total area of ​​the impurity peak. The impurity peak area is proportional to the impurity content. Compared with the simple peak height, the peak area can more comprehensively and accurately reflect the amount of impurities.

[0056] Compare and judge the previously calculated impurity peak area with the set signal-to-noise ratio standard. First, clarify the threshold or range specified by the signal-to-noise ratio standard, and then convert the calculated impurity peak area into the corresponding signal-to-noise ratio value, which usually requires considering both the signal intensity of the impurity peak and the intensity of the background noise. Finally, determine whether the converted signal-to-noise ratio meets or exceeds the set standard. If the signal-to-noise ratio corresponding to the impurity peak area meets the set standard, it means that the impurity peak is considered to be a valid and reliable signal and can be used for subsequent impurity analysis and quantitative calculations. On the contrary, if the signal-to-noise ratio standard is not met, it may be necessary to re-evaluate the detection conditions, improve the method, or consider the signal to be unreliable and cannot be used for accurate impurity analysis.

[0057] If the impurity peak area meets the set signal-to-noise ratio standard, it means that the signal of this impurity peak is valid and reliable, and the first impurity signal intensity is determined and output based on the impurity peak area that meets the standard. The purpose of this step is to convert the impurity peak area that has been verified to be valid by the signal-to-noise ratio standard into the first impurity signal intensity that can accurately reflect the impurity content or concentration.

[0058] In a possible implementation, step S600 further includes: Step S670: perform impurity impact analysis based on the impurity signal strength and the detection verification result to generate an interference signal; retrieve historical drug impurity data record logs to determine impurity type information and impurity content information; set a first impurity tolerance based on the impurity type information, the impurity content information and the first sensitivity; set a second impurity tolerance based on the impurity type information, the impurity content information and the second sensitivity; set a third impurity tolerance based on the impurity type information, the impurity content information and the third sensitivity; traverse the first impurity tolerance, the second impurity tolerance, and the third impurity tolerance to compare with the interference signal, adjust the first sensitivity, the second sensitivity, and the third sensitivity, and generate the sensitivity adjustment result.

[0059] Specifically, the impurity signal intensity and detection verification results obtained in the previous steps are obtained. The impurity signal intensity quantitatively represents the content or concentration level of the impurity, and the detection verification results contain information about the consistency and reliability of the impurity signal. Based on these data and information, the impurity impact analysis is performed, which involves studying the chemical and physical properties of impurities, as well as their behavior and effects in a specific environment or system. During the analysis process, consider the possible interactions between impurities and the main components, such as chemical reactions, physical mixing, and the effects on physical processes (such as heat transfer and mass transfer). By comprehensively evaluating these factors, the negative impact of impurities on product quality, performance, safety, etc. is determined. Finally, an interference signal is generated based on the analysis results. This interference signal can be a quantitative value indicating the degree of interference that the impurity may cause; it can also be a qualitative description, such as "mild interference" and "severe interference".

[0060] Access and retrieve logs of historical drug impurity data, which are usually data accumulated and saved during previous drug testing, production, and quality control processes. By carefully reviewing these logs, the types of impurities involved can be clearly identified. This includes descriptions of specific impurity names, chemical structures, physical properties, etc. At the same time, the content information of each impurity can also be obtained, and the impurity content is usually expressed in a quantitative manner, such as percentage, concentration, mass fraction, etc. For example, in the historical records, it was found that a drug contained impurities A, B, and C, where the content of impurity A was 0.5%, the content of impurity B was 0.2%, and the content of impurity C was 0.1%. Determining these impurity types and content information is important for evaluating the quality of current drugs, comparing the differences between different batches of drugs, improving production processes, and ensuring that drugs comply with relevant standards and regulations.

[0061] Comprehensively consider the impurity type information and impurity content information obtained. Different types of impurities have different hazards and impacts; the level of impurity content is directly related to the degree of its impact on the quality of the drug. Then, combined with the first sensitivity determined previously, the first sensitivity reflects the sensitivity and accuracy of the detection method to impurity detection. On this basis, the first impurity tolerance is set. The first impurity tolerance is a threshold or range, which indicates the maximum content or concentration that can be accepted for a certain impurity under specific detection conditions. By reasonably setting the first impurity tolerance, while ensuring the quality and safety of the drug, the production efficiency is improved and the cost is reduced, and at the same time, clear standards and basis are provided for subsequent quality control and testing work. Similarly, the second impurity tolerance is set based on the impurity type information, the impurity content information and the second sensitivity; the third impurity tolerance is set based on the impurity type information, the impurity content information and the third sensitivity.

[0062] Check the first impurity tolerance, the second impurity tolerance, and the third impurity tolerance in turn, and compare these tolerances with the interference signal. The interference signal reflects the actual impact that the impurity may have. During the comparison process, if the interference signal is found to exceed a certain impurity tolerance, it means that the current sensitivity may not be accurate or appropriate and needs to be adjusted. The adjustment of the first sensitivity, the second sensitivity, and the third sensitivity is carried out according to the degree of tolerance exceeded and the specific detection requirements. For example, if the interference signal greatly exceeds the first impurity tolerance, the first sensitivity will be significantly improved to more accurately detect and evaluate the relevant impurities. The adjustment can be made by changing the parameter settings of the detection equipment, updating the detection algorithm, optimizing the sample processing method, etc. The sensitivity adjustment result finally generated will clearly record the specific adjustments made to each sensitivity, as well as the reasons for the adjustment and the expected effects. Finally, a detailed sensitivity adjustment result is formed to provide more optimized detection conditions for subsequent impurity detection and analysis.

[0063] In a possible implementation, step S670 further includes: Step S671: Traverse the first impurity tolerance, the second impurity tolerance, and the third impurity tolerance and compare them with the interference signal to determine whether the interference signal is less than or equal to the first impurity tolerance, whether the interference signal is less than or equal to the second impurity tolerance, and whether the interference signal is less than or equal to the third impurity tolerance.

[0064] Step S672: If the interference signal is greater than the first impurity tolerance, and the interference signal is less than or equal to the second impurity tolerance, and the interference signal is less than or equal to the third impurity tolerance, then a back-calculation is performed on the sample spectrum based on the first sensitivity to generate first back-calculation data.

[0065] Step S673: Adjust the first sensitivity based on the first traceback data to generate a first sensitivity adjustment result.

[0066] Step S674: If the interference signal is less than or equal to the first impurity tolerance, and the interference signal is greater than the second impurity tolerance, and the interference signal is less than or equal to the third impurity tolerance, then a back-calculation is performed on the sample spectrum based on the second sensitivity to generate second back-calculation data.

[0067] Step S675: adjusting the second sensitivity based on the second traceback data to generate a second sensitivity adjustment result.

[0068] Step S676: If the interference signal is less than or equal to the first impurity tolerance, and the interference signal is less than or equal to the second impurity tolerance, and the interference signal is greater than the third impurity tolerance, then a back-calculation is performed on the sample spectrum based on the third sensitivity to generate third back-calculation data.

[0069] Step S677: adjusting the third sensitivity based on the third traceback data to generate a third sensitivity adjustment result.

[0070] Specifically, the interference signal will be carefully compared with the first impurity tolerance, the second impurity tolerance and the third impurity tolerance in turn. Since chromatography, spectroscopy and mass spectrometry are independent analytical techniques based on different principles, it is necessary to be very precise when adjusting the sensitivity. When the detection system finds that only one spectrum has an abnormal sensitivity, it can quickly locate the root cause of the problem. By isolating the three abnormalities, the problem can be analyzed more specifically. For example, if the sensitivity of the chromatogram is abnormal, it is caused by aging of the chromatographic column, problems with the mobile phase or detector failure; the abnormality of the spectrum is related to the performance of the light source, monochromator or detector; the abnormality of the mass spectrum is related to the stability of the ion source, mass analyzer or detection system. Based on this principle of abnormal isolation, when performing this traversal comparison, there will only be a situation where the sensitivity of one spectrum is abnormal, and it is impossible for the sensitivity of three or two spectra to be greater than the corresponding impurity tolerance. This can quickly and accurately locate the problem, providing a highly targeted direction for subsequent adjustments and improvement measures.

[0071] If the interference signal is greater than the first impurity tolerance, and less than or equal to the second impurity tolerance and the third impurity tolerance, it means that the detection result corresponding to the first sensitivity may not be accurate enough, and it is necessary to perform a retrospective calculation on the sample spectrum based on the first sensitivity. Generate the first retrospective data by reanalyzing and processing the previous detection data to find possible problems or errors. Use the generated first retrospective data to make targeted adjustments to the first sensitivity. The purpose of the adjustment is to improve the accuracy and reliability of the first sensitivity, so that it can more accurately detect and evaluate related impurities, and finally generate the first sensitivity adjustment result.

[0072] When the interference signal is less than or equal to the first impurity tolerance, greater than the second impurity tolerance, and less than or equal to the third impurity tolerance, it indicates that there is a problem with the second sensitivity. The sample spectrum is back-calculated based on the second sensitivity to obtain second back-tracing data. The second sensitivity is adjusted based on the second back-tracing data to optimize its detection performance and generate a second sensitivity adjustment result.

[0073] If the interference signal is less than or equal to the first impurity tolerance and the second impurity tolerance, but greater than the third impurity tolerance, it means that the third sensitivity needs to be improved. The sample spectrum is back-calculated based on the third sensitivity to obtain third back-calculation data. The third sensitivity is adjusted according to the third back-calculation data to generate a third sensitivity adjustment result.

[0074] In a possible implementation, step S700 further includes: Step S710: sort the first sensitivity adjustment result, the first sensitivity adjustment result, and the first sensitivity adjustment result in descending order to generate a first sequence.

[0075] Step S720: Perform weight analysis based on the first sensitivity adjustment result, the first sensitivity adjustment result, and the first sensitivity adjustment result to obtain multiple weight allocation coefficients.

[0076] Step S730: sort the first sensitivity adjustment result, the first sensitivity adjustment result, and the first sensitivity adjustment result in descending order according to the multiple weight allocation coefficients to generate a second sequence.

[0077] Step S740: normalize the first sequence and the second sequence to generate a trusted sequence.

[0078] Step S750: extract the impurity signal corresponding to the sensitivity of the first order according to the trusted sequence for detection and identification, and generate the drug impurity detection result.

[0079] Specifically, the first sensitivity adjustment result, the second sensitivity adjustment result, and the third sensitivity adjustment result are compared and arranged in descending order. For example, if the first sensitivity adjustment result is 0.5, the second sensitivity adjustment result is 0.3, and the third sensitivity adjustment result is 0.7, then the first sequence generated after descending order is: 0.7, 0.5, 0.3.

[0080] A weight analysis is performed based on the first sensitivity adjustment result, the second sensitivity adjustment result, and the third sensitivity adjustment result obtained previously. The purpose of the weight analysis is to determine the relative importance of each sensitivity adjustment result in the comprehensive evaluation. This requires comprehensive consideration of multiple factors, including historical data on the accuracy and reliability of different detection methods. If a certain detection method has shown higher accuracy and stability in multiple tests in the past, then its corresponding sensitivity adjustment result will be given a higher weight. The criticality of the impact of impurities on drug quality will also be considered. If a certain impurity poses a greater potential threat to the safety and effectiveness of the drug, then the sensitivity adjustment result of detecting the impurity may be given a higher weight. By comprehensively considering these factors, a weight allocation coefficient is calculated for each sensitivity adjustment result.

[0081] A plurality of weight distribution coefficients are obtained, corresponding to the first sensitivity adjustment result, the second sensitivity adjustment result and the third sensitivity adjustment result. The three sensitivity adjustment results are sorted in descending order again according to these weight distribution coefficients. Each sensitivity adjustment result is multiplied by its corresponding weight distribution coefficient to obtain a weighted value. For example, assuming that the first sensitivity adjustment result is A1, its weight distribution coefficient is W1; the second sensitivity adjustment result is A2, and the weight distribution coefficient is W2; the third sensitivity adjustment result is A3, and the weight distribution coefficient is W3. Then the weighted values ​​are A1×W1, A2×W2, and A3×W3, respectively. Arrange these weighted values ​​from large to small to generate a second sequence.

[0082] The first and second sequences obtained above need to be normalized to generate a trustworthy sequence. Normalization is an operation that maps data to a specific range (usually [0, 1]) to eliminate the differences in dimensions and numerical ranges between different data and make them comparable. For each element in the first and second sequences, the normalization calculation method is usually: (original value - minimum value) / (maximum value - minimum value). After processing the first and second sequences, the two sets of processed data are combined. The comprehensive method is to give each of them a certain proportion of importance, such as 40% for the first sequence and 60% for the second sequence, and then add up the numbers in the corresponding positions according to this proportion. The final comprehensive result is a trustworthy sequence. The numbers in this sequence allow us to judge and use it more fairly and reliably.

[0083] The generated trustworthy sequence is obtained through a series of processing and comprehensive calculations, reflecting the comprehensive evaluation of the results of different sensitivity adjustments. Then, check in the order of this trustworthy sequence and extract the sensitivity corresponding to the element ranked first. Find the impurity signal associated with this sensitivity and perform detection and identification operations on this impurity signal. This includes marking this signal with a specific mark, recording relevant characteristic information, and making judgments about its content or properties. Finally, the final result of drug impurity detection is generated by processing and identifying the impurity signal corresponding to this first sensitivity. By adjusting, sorting and comprehensively analyzing different sensitivities, the existence and content of impurities can be determined more accurately, reducing the possibility of misjudgment and missed judgment, and improving the accuracy and reliability of detection.

[0084] Embodiment 2 Based on the same inventive concept as the high-sensitivity drug impurity analysis and detection method in the above-mentioned embodiment, Figure 2 As shown, the present application provides a highly sensitive drug impurity analysis and detection system, and the system and method embodiments in the present application embodiments are based on the same inventive concept. The system includes: The sample data generating module 10 performs random sampling based on a plurality of drug batch information to generate a plurality of sample data.

[0085] The impurity detection network construction module 20 is used to construct an impurity detection network, and the impurity detection network is used to perform impurity detection on the multiple sample data to generate impurity signals. The impurity detection network includes a chromatographic detection channel, a spectral detection channel, and a mass spectrometry detection channel.

[0086] The sample chromatogram generating module 30 is used to synchronize the plurality of sample data to the chromatographic detection channel for analysis to generate a sample chromatogram, wherein the sample chromatogram has a first sensitivity.

[0087] The sample spectrum generating module 40 is used to synchronize the plurality of sample data to the spectrum detection channel for analysis to generate a sample spectrum, wherein the sample spectrum has a second sensitivity.

[0088] The sample mass spectrum generating module 50 is used to synchronize the plurality of sample data to the mass spectrometry detection channel for analysis to generate a sample mass spectrum, wherein the sample mass spectrum has a third sensitivity.

[0089] The sample impurity evaluation result generation module 60 evaluates the impurity signal based on the first sensitivity, the second sensitivity, the third sensitivity in combination with the sample chromatogram, the sample spectrum, and the sample mass spectrum to generate a sample impurity evaluation result.

[0090] The drug impurity detection result extraction module 70 is used to adjust the first sensitivity, the second sensitivity, and the third sensitivity according to the sample impurity evaluation result, and extract the drug impurity detection result according to the sensitivity adjustment result.

[0091] Furthermore, the sample data generating module 10 further includes: A drug batch information determination unit, the drug batch information determination unit is used to retrieve the production process of the target drug to determine multiple drug batch information. A drug batch information determination unit, the drug batch information determination unit is used to traverse the multiple drug batch information and extract according to the detection requirements of the target drug to determine N drug batch information, where N is an integer greater than 0. A random sampling unit, the random sampling unit is used to perform random sampling based on the N drug batch information, M sampling results, the M sampling results correspond to the N drug batch information, and M is an integer greater than or equal to N. A sample data generation unit, the sample data generation unit performs sample identification based on the M sampling results to generate multiple sample data.

[0092] Furthermore, the sample impurity assessment result generating module 60 further includes: A first impurity signal intensity obtaining unit, wherein the first impurity signal intensity obtaining unit performs analysis based on the first sensitivity in combination with the sample chromatogram to obtain the first impurity signal intensity. A second impurity signal intensity obtaining unit, wherein the second impurity signal intensity obtaining unit performs analysis based on the second sensitivity in combination with the sample spectrum to obtain the second impurity signal intensity. A third impurity signal intensity obtaining unit, wherein the third impurity signal intensity obtaining unit performs analysis based on the third sensitivity in combination with the sample mass spectrum to obtain the third impurity signal intensity. A detection evaluation index definition unit, wherein the detection evaluation index definition unit is used to define a detection evaluation index according to the first impurity signal intensity, the second impurity signal intensity, and the third impurity signal intensity. A detection verification result generation unit, wherein the detection verification result generation unit is used to perform signal consistency verification on the impurity signal according to the detection evaluation index to generate a detection verification result. A verification result adding unit, wherein the verification result adding unit is used to add the detection verification result to the sample impurity evaluation result.

[0093] Furthermore, the first impurity signal strength obtaining unit further includes: A signal-to-noise ratio standard setting unit, the signal-to-noise ratio standard setting unit is used to set the signal-to-noise ratio standard based on the first sensitivity. An impurity peak extraction unit, the impurity peak extraction unit identifies and extracts impurity peaks from the sample chromatogram based on a baseline correction algorithm, the impurity peaks comprising impurity retention time and impurity peak height. An impurity peak area calculation unit, the impurity peak area calculation unit calculates the impurity peak area according to the impurity retention time and the impurity peak height. A signal-to-noise ratio standard judgment unit, the signal-to-noise ratio standard judgment unit is used to judge whether the impurity peak area meets the signal-to-noise ratio standard. A first impurity signal intensity output unit, the first impurity signal intensity output unit is used to output the first impurity signal intensity according to the impurity peak area if the impurity peak area meets the signal-to-noise ratio standard.

[0094] Furthermore, the drug impurity detection result extraction module 70 also includes: An interference signal generating unit, the interference signal generating unit is used to perform an impurity impact analysis according to the impurity signal strength and the detection verification result, and generate an interference signal. An impurity information determining unit, the impurity information determining unit is used to retrieve the historical drug impurity data record log, and determine the impurity type information and impurity content information. A first impurity tolerance setting unit, the first impurity tolerance setting unit sets the first impurity tolerance based on the impurity type information, the impurity content information and the first sensitivity. A second impurity tolerance setting unit, the second impurity tolerance setting unit sets the second impurity tolerance based on the impurity type information, the impurity content information and the second sensitivity. A third impurity tolerance setting unit, the third impurity tolerance setting unit sets the third impurity tolerance based on the impurity type information, the impurity content information and the third sensitivity. A sensitivity adjustment result generating unit, the sensitivity adjustment result generating unit is used to traverse the first impurity tolerance, the second impurity tolerance, and the third impurity tolerance to compare with the interference signal, adjust the first sensitivity, the second sensitivity, and the third sensitivity, and generate the sensitivity adjustment result.

[0095] Furthermore, the sensitivity adjustment result generating unit further includes: An impurity tolerance judgment unit, the impurity tolerance judgment unit is used to traverse the first impurity tolerance, the second impurity tolerance, and the third impurity tolerance to compare with the interference signal to determine whether the interference signal is less than or equal to the first impurity tolerance, and whether the interference signal is less than or equal to the second impurity tolerance, and whether the interference signal is less than or equal to the third impurity tolerance; a first traceback data generation unit, the first traceback data generation unit is used to perform a traceback calculation on the sample spectrum based on the first sensitivity to generate first traceback data if the interference signal is greater than the first impurity tolerance, and whether the interference signal is less than or equal to the second impurity tolerance, and whether the interference signal is less than or equal to the third impurity tolerance; a first sensitivity adjustment result generation unit, the first sensitivity adjustment result generation unit adjusts the first sensitivity based on the first traceback data to generate a first sensitivity adjustment result; a second traceback data generation unit, the second traceback data generation unit is used to perform a traceback calculation on the sample spectrum based on the first sensitivity to generate first traceback data if the interference signal is greater than the first impurity tolerance, and whether the interference signal is less than or equal to the second impurity tolerance, and whether the interference signal is less than or equal to the third impurity tolerance whether the interference signal is less than or equal to the first impurity tolerance, whether the interference signal is greater than the second impurity tolerance, and whether the interference signal is less than or equal to the third impurity tolerance, then based on the second sensitivity, the sample spectrum is back-calculated to generate second back-calculation data; a second sensitivity adjustment result generating unit, the second sensitivity adjustment result generating unit adjusts the second sensitivity based on the second back-calculation data to generate a second sensitivity adjustment result; a third back-calculation data generating unit, the third back-calculation data generating unit is used to, if the interference signal is less than or equal to the first impurity tolerance, whether the interference signal is less than or equal to the second impurity tolerance, and whether the interference signal is greater than the third impurity tolerance, then based on the third sensitivity, the sample spectrum is back-calculated to generate third back-calculation data; a third sensitivity adjustment result generating unit, the third sensitivity adjustment result generating unit adjusts the third sensitivity based on the third back-calculation data to generate a third sensitivity adjustment result.

[0096] Furthermore, the drug impurity detection result extraction module 70 also includes: A first sequence generating unit, the first sequence generating unit is used to sort the first sensitivity adjustment result, the first sensitivity adjustment result, and the first sensitivity adjustment result in descending order to generate a first sequence; a weight distribution coefficient acquiring unit, the weight distribution coefficient acquiring unit performs weight analysis based on the first sensitivity adjustment result, the first sensitivity adjustment result, and the first sensitivity adjustment result to obtain a plurality of weight distribution coefficients; a second sequence generating unit, the second sequence generating unit is used to sort the first sensitivity adjustment result, the first sensitivity adjustment result, and the first sensitivity adjustment result in descending order according to the plurality of weight distribution coefficients to generate a second sequence; a trusted sequence generating unit, the trusted sequence generating unit is used to normalize the first sequence and the second sequence to generate a trusted sequence; a drug impurity detection result generating unit, the drug impurity detection result generating unit is used to extract the impurity signal corresponding to the sensitivity of the first sequence according to the trusted sequence for detection identification to generate the drug impurity detection result.

[0097] It should be noted that the above-mentioned sequence of the embodiments of the present application is only for description and does not represent the advantages and disadvantages of the embodiments. And the above-mentioned specific embodiments of this specification are described. In addition, the processes depicted in the accompanying drawings do not necessarily require the specific order or continuous order shown to achieve the desired results. In some embodiments, multitasking and parallel processing are also possible or may be advantageous.

[0098] The above description is only a preferred embodiment of the present application and is not intended to limit the present application. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present application should be included in the protection scope of the present application.

[0099] This specification and the drawings are merely exemplary illustrations of the present application and are deemed to cover any and all modifications, variations, combinations or equivalents within the scope of the present application. Obviously, a person skilled in the art may make various modifications and variations to the present application without departing from the scope of the present application. Thus, if these modifications and variations of the present application fall within the scope of the present application and its equivalents, the present application intends to include these modifications and variations.

Claims

1. A highly sensitive drug impurity analysis and detection method, characterized in that: The method comprises: Perform random sampling based on multiple drug batch information to generate multiple sample data; Constructing an impurity detection network, wherein the impurity detection network is used to perform impurity detection on the plurality of sample data to generate an impurity signal, wherein the impurity detection network comprises a chromatographic detection channel, a spectral detection channel, and a mass spectrometry detection channel; Synchronize the plurality of sample data to the chromatographic detection channel for analysis to generate a sample chromatogram, wherein the sample chromatogram has a first sensitivity; Synchronize the plurality of sample data to the spectrum detection channel for analysis to generate a sample spectrum graph, wherein the sample spectrum graph has a second sensitivity; Synchronizing the plurality of sample data to the mass spectrometry detection channel for analysis to generate a sample mass spectrum having a third sensitivity; Based on the first sensitivity, the second sensitivity, the third sensitivity combined with the sample chromatogram, the sample spectrum, and the sample mass spectrum, the impurity signal is evaluated to generate a sample impurity evaluation result; The first sensitivity, the second sensitivity, and the third sensitivity are adjusted according to the sample impurity evaluation result, and the drug impurity detection result is extracted according to the sensitivity adjustment result.

2. A highly sensitive drug impurity analysis and detection method as claimed in claim 1, characterized in that: Based on the multiple drug batch information, random sampling is performed to generate multiple sample data, and the method includes: Retrieve the production process of the target drug to determine multiple drug batch information; Traversing the plurality of drug batch information and extracting them according to the detection requirements of the target drug, and determining N drug batch information, where N is an integer greater than 0; Random sampling is performed according to the N drug batch information to obtain M sampling results, and the M sampling results correspond to the N drug batch information, where M is an integer greater than or equal to N; Sample identification is performed based on the M sampling results to generate multiple sample data.

3. A highly sensitive drug impurity analysis and detection method as claimed in claim 1, characterized in that: The impurity signal is evaluated based on the first sensitivity, the second sensitivity, the third sensitivity in combination with the sample chromatogram, the sample spectrum, and the sample mass spectrum to generate a sample impurity evaluation result, the method comprising: Performing analysis based on the first sensitivity combined with the sample chromatogram to obtain a first impurity signal intensity; Performing analysis based on the second sensitivity combined with the sample spectrum to obtain a second impurity signal intensity; Performing analysis based on the third sensitivity in combination with the sample mass spectrum to obtain a third impurity signal intensity; Defining a detection evaluation index according to the first impurity signal strength, the second impurity signal strength, and the third impurity signal strength; Performing signal consistency verification on the impurity signal according to the detection evaluation index to generate a detection verification result; The assay validation results are added to the sample impurity assessment results.

4. A highly sensitive drug impurity analysis and detection method as claimed in claim 3, characterized in that: Based on the first sensitivity and in combination with the sample chromatogram, an analysis is performed to obtain a first impurity signal intensity, the method comprising: setting a signal-to-noise ratio standard based on the first sensitivity; Identify and extract impurity peaks from the sample chromatogram based on a baseline correction algorithm, wherein the impurity peaks include impurity retention time and impurity peak height; Calculate the impurity peak area according to the impurity retention time and the impurity peak height; Determining whether the impurity peak area meets the signal-to-noise ratio standard; If the impurity peak area meets the signal-to-noise ratio standard, the first impurity signal intensity is output according to the impurity peak area.

5. A highly sensitive drug impurity analysis and detection method as claimed in claim 3, characterized in that: The first sensitivity, the second sensitivity, and the third sensitivity are adjusted according to the sample impurity evaluation result, and the method includes: Perform impurity impact analysis according to the impurity signal strength and the detection verification result to generate an interference signal; Retrieve historical drug impurity data record logs to determine impurity type information and impurity content information; Setting a first impurity tolerance based on the impurity type information, the impurity content information and the first sensitivity; Setting a second impurity tolerance based on the impurity type information, the impurity content information and the second sensitivity; Setting a third impurity tolerance based on the impurity type information, the impurity content information and the third sensitivity; The first impurity tolerance, the second impurity tolerance, and the third impurity tolerance are traversed and compared with the interference signal, and the first sensitivity, the second sensitivity, and the third sensitivity are adjusted to generate the sensitivity adjustment result.

6. A highly sensitive drug impurity analysis and detection method as claimed in claim 5, characterized in that: The method comprises: traversing the first impurity tolerance, the second impurity tolerance, and the third impurity tolerance to compare with the interference signal, adjusting the first sensitivity, the second sensitivity, and the third sensitivity, and generating the sensitivity adjustment result. Traversing the first impurity tolerance, the second impurity tolerance, and the third impurity tolerance to compare with the interference signal, and determining whether the interference signal is less than or equal to the first impurity tolerance, whether the interference signal is less than or equal to the second impurity tolerance, and whether the interference signal is less than or equal to the third impurity tolerance; If the interference signal is greater than the first impurity tolerance, and the interference signal is less than or equal to the second impurity tolerance, and the interference signal is less than or equal to the third impurity tolerance, then performing a backtracking calculation on the sample spectrum based on the first sensitivity to generate first backtracking data; Adjust the first sensitivity based on the first traceback data to generate a first sensitivity adjustment result; If the interference signal is less than or equal to the first impurity tolerance, and the interference signal is greater than the second impurity tolerance, and the interference signal is less than or equal to the third impurity tolerance, then performing a backtracking calculation on the sample spectrum based on the second sensitivity to generate second backtracking data; Adjust the second sensitivity based on the second traceback data to generate a second sensitivity adjustment result; If the interference signal is less than or equal to the first impurity tolerance, and the interference signal is less than or equal to the second impurity tolerance, and the interference signal is greater than the third impurity tolerance, then performing a backtracking calculation on the sample spectrum based on the third sensitivity to generate third backtracking data; The third sensitivity is adjusted based on the third traceback data to generate a third sensitivity adjustment result.

7. A highly sensitive drug impurity analysis and detection method as claimed in claim 6, characterized in that: Extracting drug impurity test results based on sensitivity adjustment results, the method includes: Sort the first sensitivity adjustment result, the second sensitivity adjustment result, and the first sensitivity adjustment result in descending order to generate a first sequence; Perform weight analysis based on the first sensitivity adjustment result, the second sensitivity adjustment result, and the first sensitivity adjustment result to obtain a plurality of weight allocation coefficients; Sort the first sensitivity adjustment result, the second sensitivity adjustment result, and the first sensitivity adjustment result in descending order according to the multiple weight distribution coefficients to generate a second sequence; Normalizing the first sequence and the second sequence to generate a trustworthy sequence; The impurity signal corresponding to the sensitivity of the first order is extracted according to the trusted sequence for detection and identification, and the drug impurity detection result is generated.

8. A highly sensitive drug impurity analysis and detection system, characterized in that: The system is used to implement a highly sensitive drug impurity analysis and detection method according to any one of claims 1 to 7, and the system comprises: A sample data generation module, wherein the sample data generation module generates a plurality of sample data by performing random sampling based on a plurality of drug batch information; An impurity detection network construction module, wherein the impurity detection network construction module is used to construct an impurity detection network, wherein the impurity detection network is used to perform impurity detection on the plurality of sample data to generate an impurity signal, wherein the impurity detection network comprises a chromatographic detection channel, a spectral detection channel, and a mass spectrometry detection channel; A sample chromatogram generation module, the sample chromatogram generation module is used to synchronize the multiple sample data to the chromatographic detection channel for analysis, and generate a sample chromatogram, the sample chromatogram having a first sensitivity; A sample spectrum generating module, the sample spectrum generating module is used to synchronize the plurality of sample data to the spectrum detection channel for analysis, and generate a sample spectrum, the sample spectrum having a second sensitivity; A sample mass spectrum generation module, the sample mass spectrum generation module is used to synchronize the multiple sample data to the mass spectrometry detection channel for analysis, and generate a sample mass spectrum, the sample mass spectrum having a third sensitivity; a sample impurity evaluation result generating module, wherein the sample impurity evaluation result generating module evaluates the impurity signal based on the first sensitivity, the second sensitivity, the third sensitivity in combination with the sample chromatogram, the sample spectrum, and the sample mass spectrum to generate a sample impurity evaluation result; A drug impurity detection result extraction module is used to adjust the first sensitivity, the second sensitivity, and the third sensitivity according to the sample impurity evaluation result, and extract the drug impurity detection result according to the sensitivity adjustment result.

Citation Information

Patent Citations

  • Fingerprint spectrum similarity calculation method and device and sample quality evaluation system

    CN107784192A

  • Mopirocin ointment impurity qualitative positioning and testing method and application

    CN111220721A

  • Method for detecting M protein in serum based on liquid chromatography-mass spectrometry

    CN118443838A

  • Method for detecting genotoxic impurities in biapenem

    CN118604173A

  • Pyrrolidone product impurity analysis method

    CN118604203A

Cited By

  • Associated imaging impurity detection method and system for drug production

    CN120971448A

  • A method and system for detecting process-related imaging impurities in pharmaceutical production

    CN120971448B